Friday, February 17, 2023 3:55:10 PM
Don't know if this has been mentioned here already or not - but Sarissa and Denner look like they pulled a fast one on us - they actually dumped 19M shrs in Q4, partly why there was so much selling pressure on the stock, then bought 21M shrs back in the first week or two of 2023 - so they were arguing since Oct 2022 as a 5% owner they could demand a special shareholder meeting, which they actually didn't file for until Jan 11 2023, while in reality during some period of time in Q4/22 they only owned 1% of AMRN - appears they sold at $1.20 or so to help drive the price down so they could get shareholders riled up enough to elect their BOD, then the rebought at $1.40 or more - that was pps as of 1/4/23, went all the way up to $2120 on 1/17:
https://whalewisdom.com/stock/amrn
SARISSA CAPITAL MANAGEMENT LP
Shares Held Change in Shares % Ownership Date Reported
4,807,000 19,191,000 1.1904% (no date given, it's their 13F for Q4/22)
25,210,000 (no change in # shrs reported, very odd) 6.2427% 2023-02-14
I checked a bunch of different websites, some show that 19M shr sale in Q4, some don't, but all show Sarissa controlling 6.24% as of 2/14/23 - but I suddenly think maybe I should change my vote to the white card, Denner is apparently a real snake in the grass.
https://whalewisdom.com/stock/amrn
SARISSA CAPITAL MANAGEMENT LP
Shares Held Change in Shares % Ownership Date Reported
4,807,000 19,191,000 1.1904% (no date given, it's their 13F for Q4/22)
25,210,000 (no change in # shrs reported, very odd) 6.2427% 2023-02-14
I checked a bunch of different websites, some show that 19M shr sale in Q4, some don't, but all show Sarissa controlling 6.24% as of 2/14/23 - but I suddenly think maybe I should change my vote to the white card, Denner is apparently a real snake in the grass.
The Thought Police: To censor and protect. Craig Bruce
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
